Connor, Clark & Lunn Investment Management (CC&L)’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-49,068
| Closed | -$3.21M | – | 1257 |
|
|
2022
Q3 | $3.21M | Buy |
49,068
+36,857
| +302% | +$2.41M | 0.02% | 406 |
|
|
2022
Q2 | $742K | Sell |
12,211
-21,110
| -63% | -$1.28M | ﹤0.01% | 689 |
|
|
2022
Q1 | $2.09M | Buy |
+33,321
| New | +$2.09M | 0.01% | 492 |
|
|
2021
Q4 | – | Sell |
-116,485
| Closed | -$13M | – | 1099 |
|
|
2021
Q3 | $13M | Buy |
116,485
+19,343
| +20% | +$2.17M | 0.07% | 199 |
|
|
2021
Q2 | $15.7M | Buy |
97,142
+91,999
| +1,789% | +$14.9M | 0.08% | 191 |
|
|
2021
Q1 | $627K | Buy |
+5,143
| New | +$627K | ﹤0.01% | 762 |
|